Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Nitrogen containing other than solely as a nitrogen in an...
Reexamination Certificate
2007-09-04
2007-09-04
Padmanabhan, Sreeni (Department: 1617)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Nitrogen containing other than solely as a nitrogen in an...
C514S923000
Reexamination Certificate
active
10614344
ABSTRACT:
Preparations and extracts of valerian, as well as isovaleramide, isovaleric acid, and certain structurally related compounds, exhibit clinically significant pharmacological properties that implicate a treatment for a variety of pathological conditions, including spasticity and convulsions, which are ameliorated by effecting a modulation of CNS activity. The compositions in question generally are non-cytotoxic and do not elicit weakness or sedative activity at doses that are effective for the symptomatic treatment of such pathological conditions.
REFERENCES:
patent: 3485851 (1969-12-01), Thies
patent: 4933324 (1990-06-01), Shashoua
patent: 4939174 (1990-07-01), Shashoua
patent: 5506268 (1996-04-01), Balandrin et al.
patent: 5763494 (1998-06-01), Balandrin et al.
patent: 5994392 (1999-11-01), Shashoua
patent: 6107499 (2000-08-01), Shashoua
patent: 6258836 (2001-07-01), Shashoua
patent: 6589994 (2003-07-01), Artman et al.
patent: 94/28888 (1994-12-01), None
patent: 94 28888 (1994-12-01), None
patent: WO94/28888 (1994-12-01), None
patent: 97/34596 (1997-09-01), None
patent: WO97/34596 (1997-09-01), None
patent: 98/08498 (1998-03-01), None
patent: 98 08498 (1998-03-01), None
patent: WO98/08498 (1998-03-01), None
patent: WO99/44623 (1999-03-01), None
patent: WO 01/28516 (2000-10-01), None
Schon and Blau, J Neurol Neurosurg Psychiatry, Sep. 1987: 50(9):1148-1152.
Dorland's Medical Dictionary 27th ed. p. 379.
Pharmacotherapy, A Pathophysiologic Approach, Dipiro et al.2nd ed. 1991, pp. 1232, 1238).
Drug facts and comparisons 1999 ed. pp. 1595-1597(“Drug Facts”).
Pharmacotherapy, A Pathophysiologic Approach, Dipiro et al. 2nded. 1991, pp. 1232 & 1238.
Drug Facts and Comparisons. 1999 ed. pp. 1595-1597 (“Drug Facts”).
Julius A. Vida “Advances in Anticonvulsant Drug Development”; Anticonvulsants (1997) pp. 1-9; Academic Press.
Julius A. Vida “Noncyclic Anticonvulsants”; Anticonvulsants (1977) pp. 577-619; Academic Press.
Salim Hadad, et al. “Pharmacokinetic Analysis and Antiepileptic Activity of N-Valproyl Deriatives of GABA and Glycine”; Pharmaceutical Research (1995), pp. 905-907; Plenum Publishing Corporation.
Abdulla Haj-Yehia, et al. “Structure-Pharmacokinetic Relationships in a Series of Short Fatty Acid Amides that Possess Anticonvulsant Activity”; Journal Of Pharmaceutical Sciences; (Aug. 1990); pp. 719-724; vol. 79, No. 8.
Abdulla Haj-Yehia, et al. “Pharmacokinetic Analysis of the Structural Requirements for Forming “Stable” Analogues of Valpromide”; Pharmaceutical Research; (1992) pp. 1058-1063; vol. 9, No. 8; Plenum Publishing Corporation.
Georges Taillandier, et al. “Recherches dans la série dipropylacétique XII. Acides et alcools aliphatiques ramifiés anticonvulsivants”; Eur. J. Med. Chem—Chemical Therapeutica; (Sep.-Oct. 1975-10); N° 5; pp. 453-462.
Joel G. Hardman, Ph.D., et al. “The Pharmacological Basis of Therapeutics” 10thEdition; (2001).
H. Steve White, et al. “Experimental Selection, Quantification, and Evaluation of Antiepileptic Drugs” Antiepileptic Drugs, Fourth Edition; (1995); pp. 99-110; Raven Press, New York.
Walter Sneader “Drug Discovers: The Evolution of Modern Medicines” (1985), pp. 24-47; John Wil y & Sons.
Julius A. Vida “Anticonvulsants”; Principles Of Modern Chemistry, 4thEdition; (1995); pp. 182-198; Williams and Wilkins.
David A. Williams, et al. (Table of Contents) “Foye's Principles of Medicinal Chemistry” 5thEdition (2002).
W. Löscher, et al. “Strategies in antiepileptic drug development: is rational drug design superior to random screening and structural variation?” Epilepsy Research; (1994) pp. 95-134.
A. Haj-Yehia, et al. “Structure-pharmacokinetic relationships in a series of valpromide derivatives with antiepileptic activity” PMID: 2510141 [PubMed—indexed for MEDLINE].
A. Haj-Yehia, et al. “Structure-pharmacokinetic relationships in a series of short fatty acid amides that possess anticonvulsant activity” PMID: 2231336 [PubMed—indexed for MEDLINE].
Abdulla Haj-Yehia, et al. “Structure-Pharmacokinetic Relationship in a Series of Valpromide Derivatives with Antiepileptic Activity”; Pharmaceutical Research; vol. 6, No. 8, (1989) pp. 683-689; Plenum Publishing Corporation.
Heinz Nau, et al. “Pharmacologic Evaluation of Various Metabolites and Analogs of Valproic Acid: Teratogenic Potencies in Mice”; Fundamental And Applied Toxicology; 6, 669-676 (1986).
P.E. Keane, et al. “Effect of Valproate on Brain Gaba: Comparison with Various Medium Chain Fatty Acids”; Pharmacological Research Communications; vol. 17, No. 6 (1985) pp. 547-555.
Meir Bailer, et al. “Can We Develop Improved Derivatives of Valproc Acid?”; Pharmacy World Science (1994) 16(1) 2-6.
Nina Isoherranen, et al. “Anticonvulsant Profile and Teratogenicity ofN-methylcyclopropyl Carboxamide: A New Antiepileptic Drug”; Epilesia; vol. 43, No. 2, pp. 115-126 (2002); Blackwell Publishing, Inc.
Micha Levi, et al. “Pharmacokinetics and Antiepileptic Activity of Valproyl Hydroxamic Acid Derivatives”; Pharmaceutical Research; vol. 14, No. 2 (1997); pp. 213-217.
Meir Bialer, et al. “Pharmacokinetic Analysis of Tetra-Methylcyclopropane Analogues of Valpromide”I Pharmaceutical Research; vol. 13, No. 2 (1996); pp. 284-289.
P. E. Keane et al., “Effect of Valproate on brain GABA: Comparison With Various Medium Chain Fatty Acids.”, Pharmacological Research Communications, Italian Pharmacological Society, vol. 17, No. 6, Jun. 1, 1985, pp. 547-555, XP-002049841.
Georges Taillandier et al., “Recherches dans la série dipropylacétique XII. Acides et alcools aliphatiques ramiflés anticonvulsivants.”, European Journal of Medicinal Chemistry Chimica Therapeutica, FR, Editions Scientifique Elsevier, Paris, vol. 10, No. 5, Sep. 1, 1975, pp. 453-462, XP-002049847.
N. Fursah et al., “Valepotriates Of Some Valerianaceae Batsch Species and Preparing Formulations on the Basis Thereof,”Pharmacia, vol. 41, No. 5, pp. 69-74, 1992.
V. Dunaev et al., “Biological Activity Of the Sum Of Valeipotriates Isolated From Valeriana Alliariifolia Adams,”Pharmacology and Toxicolgy, No. 6, pp. 33-37, 1987.
USDA A.R.S. Dr. Duke's Phyto Chemical and Ethnobotani Cal Databases Chemicals and Their Biological Activities in: Valerian Officinalis—Common Valerian, Oct. 20, 1999.
F. Fonnum, Biochemistry, Anatomy and Pharmacology of GABA Neurons, in Psychopharmacology the Third Generation of Progress, Raven Press, 1987, pp. 173-195.
J. M. Cedarbaum et al. “Drugs for Parkin's Disease, Spasticity and Acute Muscle Spasms”, in Goodman And Gilman's The Pharm. Basis of Thera., pp. 463-484, 1990.
J. W. Lance, Symposium synopsis in Spasticity—Disordered motor control, Feldman et al. (Eds), 1980, pp. 485-494.
R. Bernasconi et al., in Anticonvulsants in Affective Disorders, pp. 14-32, (Excerpta Medica 1984).
K. L. Casey, “Pain and Central Nervous System Disease: A Summary and Overview”, in Pain and Central Nervous System Disease: The Central Pain Syndromes, Raven Press, 1991, pp. 1-11.
A. Danek et al., “Restless Legs Syndrome”, Chapter 70, in Neurological Disorders: Course and Treatment, 1996, pp. 819-823.
P. D. Lyden, “GABA and Neuroprotection”, Chapter 10, in Neuroportective Agents and Cerebral Ischaemia, IRN 40, 1997, pp. 233-258.
W. A. Hauser, “Risk Factors for Epilepsy, Chapter 1”, in The Epilepsies Etiologies and Prevention, 1999 pp. 1-11.
V. E. Tyler et al., Pharmacognosy, 9thed. (Lea and Febiger 1988), pp. 456-494.
H. A. Hare et al., The National Standard Dispensatory, 1905, pp. 93, 94, 159, 160, 169, 256, 642, 692-694, 766, 767, 1031, 1383, 1384, 1426, 1479, 1480, 1571, 1572, 1619-1620, 1631-1633, 1661-1662.
D.
Artman Linda D.
Balandrin Manuel
Smith Robert L.
Claytor Renee
NBS Pharmaceuticals, Inc.
Padmanabhan Sreeni
TraskBritt
LandOfFree
Treating a variety of pathological conditions, including... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Treating a variety of pathological conditions, including..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Treating a variety of pathological conditions, including... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3797436